First in human clinical trial assessing iTOL 102

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Mar 2025 According to an iTolerance, Inc media release, company received US $1.0 million grant from BIRD foundation, the funding will be used to support clinical application of iTOL-102.
10 Mar 2025 New trial record
25 Feb 2025 According to NLS Pharmaceutics media release, the company announced that Kadimastem and iTolerance successfully completes a pre-IND meeting with the US FDA for iTOL 102 for the treatment of type 1 diabetes mellitus and in preparation of this first in human trial

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com